Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Clinical Trial of Human CD19 Targeted T Cells Injection for Subjects With Relapsed and Refractory CD19-positive Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Brief Summary: To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive diffuse large B-cell lymphoma and follicular lymphoma. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.


Options:
A: Arm Label: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
B: Arm Label: Human CD19 targeted T Cells Injection; Type: EXPERIMENTAL; Interventions: Drug: Human CD19 targeted T Cells Injection | Intervention Type: DRUG; Name: Human CD19 targeted T Cells Injection; Assigned to Arm(s): Human CD19 targeted T Cells Injection
C: Arm Label: Axicabtagene Ciloleucel and Rituximab Combination; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Rituximab, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: BIOLOGICAL; Name: Axicabtagene Ciloleucel; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination
D: Arm Label: Tisagenlecleucel; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel, Drug: lymphodepleting chemotherapy, Drug: Bridging Therapy | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel | Intervention Type: DRUG; Name: lymphodepleting chemotherapy; Assigned to Arm(s): Tisagenlecleucel | Intervention Type: DRUG; Name: Bridging Therapy; Assigned to Arm(s): Tisagenlecleucel

Answer: B